Sight Sciences(SGHT.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Sight Sciences
SGHT.US
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, as well as for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and SION surgical instrument, a bladeless manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The company also provides TearCare system, a dry eye device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality.
1.376 T
SGHT.USMarket value -Rank by Market Cap -/-

Financial Score

17/01/2026 Update
C
Health Care EquipmentIndustry
Industry Ranking71/176
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-57.91%E
    • Profit Margin-60.63%E
    • Gross Margin86.39%A
  • Growth ScoreD
    • Revenue YoY-4.39%D
    • Net Profit YoY8.42%C
    • Total Assets YoY-19.04%E
    • Net Assets YoY-32.30%E
  • Cash ScoreD
    • Cash Flow Margin-164.94%D
    • OCF YoY-4.39%D
  • Operating ScoreB
    • Turnover0.59B
  • Debt ScoreC
    • Gearing Ratio44.70%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sight Sciences | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 20.3 M

    LB filings·
    US
    SGHT
    -1.97%
    LB filings·
    US
    SGHT
    -1.97%

    Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights | SGHT Stock News

    Sight Sciences, Inc. announced preliminary, unaudited financial highlights for Q4 and full year 2025. Q4 revenue is projected between $20.3M and $20.4M, a 7% increase year-over-year, while full year revenue is expected to be $77.3M to $77.4M, a 3% decrease. Surgical Glaucoma revenues are flat, and Dry Eye revenues increased significantly. The company reported cash and equivalents of approximately $92M. CEO Paul Badawi expressed confidence in growth and operational discipline, aiming for cash flow breakeven without additional equity capital. Full results will be announced in March 2026.

    StockTitan·
    US
    SGHT
    -1.97%
    StockTitan·
    US
    SGHT
    -1.97%

    Sight Sciences, Inc. (NASDAQ:SGHT) Given Average Rating of "Hold" by Brokerages

    Sight Sciences, Inc. (NASDAQ:SGHT) has received a consensus rating of "Hold" from eight analysts. The average price target is $8.30, with one sell, three hold, and four buy recommendations. Recent price targets include UBS raising it to $12.00 and Citigroup to $9.10. Insider selling includes EVP Brenton Taylor and CFO James Rodberg. Institutional investors own 55.51% of the stock. The stock is currently down 4.6%, trading at $7.18, with a market cap of $379.61 million and a PE ratio of -7.98. The company reported a loss of $0.81 per share last quarter.

    Market Beat·
    US
    SGHT
    -1.97%
    Market Beat·
    US
    SGHT
    -1.97%

    Jeremy Hayden Sells 1,785 Shares of Sight Sciences (NASDAQ:SGHT) Stock

    Jeremy Hayden, an insider at Sight Sciences, Inc. (NASDAQ:SGHT), sold 1,785 shares at an average price of $7.48, totaling $13,351.80. Post-sale, he retains 245,420 shares valued at approximately $1.84 million, marking a 0.72% decrease in ownership. The transaction was disclosed to the SEC. Sight Sciences' stock traded down to $7.47, with a market cap of $394.94 million. Analysts have mixed sentiments, with Piper Sandler upgrading the stock to Overweight, while Weiss Ratings maintains a 'sell' rating. The average target price is $8.30, with four analysts rating it as a Buy.

    Market Beat·
    US
    SGHT
    -1.97%
    Market Beat·
    US
    SGHT
    -1.97%

    BUZZ-Piper Sandler upgrades Sight Sciences on strong business prospects

    Piper Sandler has upgraded Sight Sciencesto "overweight" from "neutral," highlighting strong prospects for its TearCare and surgical glaucoma businesses. The price target is raised to $9 from $5, indicating over 20% upside. Sight Sciences shares rose 5.2% to $7.87 premarket. While the long-term outlook for TearCare is positive, caution is advised as the company seeks insurance reimbursement. Currently, 3 of 7 brokerages rate SGHT as "buy" or higher, with a median price target of $8.55. Over the past year, the stock has declined by 5.7%.

    Reuters·
    US
    SGHT
    -1.97%
    Reuters·
    US
    SGHT
    -1.97%
    © 2026 Longbridge｜Disclaimer